Reported about 2 months ago
Pfizer's stock has significantly underperformed the market, dropping 32% over the last three years, and recent setbacks in its combination vaccine trials have raised concerns. Despite a slump in sales from its COVID-19 vaccine, the company still holds promise with its oncology segment, which is projected to grow. Currently, its stock is trading at a low valuation, making it an appealing option for potential investors, albeit with caution due to ongoing challenges.
Source: YAHOO